NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade

By: via Benzinga
NewLink Genetics Corp (NASDAQ: NLNK) said Friday it will review the clinical programs for its indoximod therapy after rival Incyte ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.